Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRenalytix Plc Regulatory News (RENX)

Share Price Information for Renalytix Plc (RENX)

Share Price is delayed by 15 minutes
Get Live Data
1.90    0.00 (0.00%)
Bid:
1.80
Ask:
2.00
Spread: 0.20 (11.111%)
Market Cap: £8.30m
RENX Live PriceLast checked at - London Stock Exchange

Intraday Renalytix Plc Share Chart

Form 8.5 (EPT/RI)-Renalytix Plc

17 Jun 2024 10:08

Form 8.5 (EPT/RI)-Renalytix Plc

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Name of exempt principal trader:Investec Bank plc
(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereeRenalytix plc
(c) Name of the party to the offer with which exempt principal trader is connected:Investec is Joint Broker to Renalytix plc
(d) Date dealing undertaken: 14th June 2024
(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer? If it is a cash offer or possible cash offer, state “N/A” N/A

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant securityPurchases/ sales Total number of securitiesHighest price per unit paid / received (pence)Lowest price per unit paid / received (pence)
Ordinary Shares Purchase 21,888 18.98 18.725

(b) Cash-settled derivative transactions

Class of relevant securityProduct description e.g. CFDNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit
     

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitType e.g. American, European etc.Expiry dateOption money paid/ received per unit
        

(ii) Exercise

Class of relevant securityProduct description e.g. call optionExercising/ exercised againstNumber of securitiesExercise price per unit
     

(d) Other dealings (including subscribing for new securities)

Class of relevant securityNature of dealing e.g. subscription, conversionDetailsPrice per unit (if applicable)
    

3. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”
 

Date of disclosure:17th June 2024
Contact name:Abhishek Gawde
Telephone number:+91 9923757332

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at.

Date   Source Headline
27th Jun 20251:09 pmRNSHolding(s) in Company
26th Jun 202511:48 amRNSHolding(s) in Company
17th Jun 20257:00 amRNSkidneyintelX.dkd data presented at ERA Congress
3rd Jun 20257:00 amRNSGrowing collaboration with NYKHM
30th May 202512:38 pmRNSHolding(s) in Company
29th May 202512:35 pmRNSHolding(s) in Company
27th May 202512:43 pmRNSHolding(s) in Company
20th May 20257:00 amRNSFirst use of KidneyIntelX in new CKD therapy trial
16th May 20253:10 pmRNSHolding(s) in Company
29th Apr 202511:03 amRNSHolding(s) in Company
22nd Apr 202512:47 pmRNSHolding(s) in Company
17th Apr 20252:56 pmRNSHolding(s) in Company
17th Apr 20257:00 amRNSHolding(s) in Company
16th Apr 20257:00 amRNSLate Breaking KidneyIntelX data show care impact
10th Apr 20257:00 amRNSQ3 Trading Update
9th Apr 20251:58 pmRNSHolding(s) in Company
7th Apr 202511:33 amRNSHolding(s) in Company
31st Mar 20251:21 pmRNSHolding(s) in Company
25th Mar 20252:59 pmRNSHolding(s) in Company
21st Mar 20251:34 pmRNSHolding(s) in Company
20th Mar 20254:19 pmRNSHolding(s) in Company
18th Mar 20257:00 amRNSHalf-year Report
12th Mar 202512:00 pmRNSNotice of Interim Results & Investor Presentation
12th Feb 20251:46 pmRNSHolding(s) in Company
11th Feb 202512:52 pmRNSHolding(s) in Company
6th Feb 20257:00 amRNS-RPublication in journal (JASN) for kidneyIntelX.dkd
28th Jan 20251:26 pmRNSHolding(s) in Company
27th Jan 20257:00 amRNSTrading Update
17th Jan 20257:00 amRNSForeign Private Issuer re-qualification
30th Dec 20241:22 pmRNSGrant & Cancellation of Options
20th Dec 20244:27 pmRNSDirector/PDMR share purchase
19th Dec 202411:16 amRNSResult of AGM
19th Dec 20247:00 amRNSAGM Statement
17th Dec 20243:53 pmRNSHolding(s) in Company
11th Dec 202411:46 amRNSDirector/PDMR dealings
9th Dec 20245:27 pmRNSDirector/PDMR share purchase
6th Dec 20247:00 amRNSDirector/PDMR share purchase
4th Dec 202412:35 pmRNSDirector/PDMR share purchase
2nd Dec 20247:00 amRNSDirectorate Change
26th Nov 20242:06 pmRNSHolding(s) in Company
26th Nov 20247:00 amRNSPublication of Annual Report and Notice of AGM
25th Nov 20246:23 pmRNSHolding(s) in Company
21st Nov 20247:00 amRNSAudited Full Year Fiscal 2024 Results
20th Nov 20247:00 amRNSFinancial Results for Q1 of Fiscal Year 2025
8th Nov 20249:31 amRNSHolding(s) in Company
7th Nov 20244:35 pmRNSHolding(s) in Company
7th Nov 20241:20 pmRNSHolding(s) in Company
6th Nov 20242:25 pmRNSCancellation of Ordinary Shares & TVR
5th Nov 20247:00 amRNSDirectorate Change
5th Nov 20247:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.